Inhibikase Therapeutics (IKT) Earnings Analysis

Inhibikase Therapeutics (IKT) next reports earnings on 2026-08-13, consensus EPS -0.09 USD. Last quarter (2026-03-26) it beat with EPS -0.09 USD vs -0.12 USD est (+25%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -4.02.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does IKT next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.09 USD
Revenue estimaten/a

IKT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-26-0.09 USD-0.12 USD+25%Beat
2025-11-14-0.13 USD-0.13 USD0%Beat
2025-08-14-0.11 USD-0.09 USD-22.2%Miss
2024-11-14-0.65 USD-0.38 USD-71.1%Miss
2024-08-14-0.66 USD-0.58 USD-13.8%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

IKT valuation and analyst view

Trailing P/E-4.02
Trailing EPS-0.51837 USD
Price / book1.27
Dividend yield0.00%
Market cap0.29B
Analyst consensusHold (0 buy / 2 hold / 0 sell)
Avg price target5 USD

Related research pages

Frequently asked questions

When is Inhibikase Therapeutics (IKT)'s next earnings date?

Inhibikase Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.09 USD.

Did IKT beat earnings last quarter?

In its 2026-03-26 report, IKT posted EPS of -0.09 USD versus a -0.12 USD estimate — a beat of 25%.

What is IKT's earnings track record?

Over the last 5 reported quarters with consensus data, IKT beat estimates 2 times (40%).

What is IKT's current P/E ratio and EPS?

IKT trades at a trailing P/E of -4.02 on trailing EPS of -0.5183724494887051 USD.

What do analysts rate IKT?

Analyst consensus is "Hold" across 2 ratings (0 strong buy, 0 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 5 USD.